Indiana AG Rokita Sues to Block Federal Cannabis Rescheduling in 2026

The Indiana AG Rokita cannabis lawsuit has put the most consequential federal drug-policy decision in half a century back on shaky legal ground. On May 22, 2026, Indiana Attorney General Todd Rokita joined attorneys general from Nebraska and Louisiana in a petition filed with the U.S. Court of Appeals for the District of Columbia Circuit, asking the court to block the Justice Department's reclassification of cannabis from Schedule I to Schedule III of the Controlled Substances Act.

The filing came just weeks after the Department of Justice finalized the long-anticipated move that pharmaceutical, medical, and state-licensed cannabis operators have spent more than a decade lobbying for. If Rokita and his coalition prevail, the rescheduling could be vacated and remanded, sending one of the most economically significant federal cannabis policy changes in U.S. history back to square one.

What the Rokita Petition Actually Argues

Rokita's complaint does not challenge the underlying scientific or medical evidence that drove the Drug Enforcement Administration and the Department of Health and Human Services to recommend Schedule III. Instead, it focuses on procedural grounds — arguing the DEA and DOJ failed to follow the rulemaking process required by the Administrative Procedure Act and the Controlled Substances Act.

The petition raises three central claims. First, that DOJ relied on an incomplete administrative record by truncating the formal hearing process that began in early 2025. Second, that the agency improperly relied on a recommendation from HHS without independent scientific evaluation by the DEA. Third, that the rescheduling violates U.S. obligations under international drug control treaties, including the 1961 Single Convention on Narcotic Drugs.

Rokita's office framed the action as a defense of state sovereignty. Indiana remains one of a shrinking number of states with no medical cannabis program and no path to adult use, and Rokita has argued repeatedly that federal rescheduling weakens his ability to enforce state-level cannabis prohibition.

Why Three States — and Why These Three

The coalition behind the petition is small but strategically chosen. Nebraska, Louisiana, and Indiana share an important regulatory posture: all three have either no functional adult-use program or face active political resistance to one. Each is also positioned to argue that Schedule III creates downstream tax, banking, and interstate-commerce effects they did not consent to.

Nebraska legalized medical cannabis through a 2024 ballot measure that the state legislature has since hobbled with restrictive rules. Louisiana operates a tightly limited medical program and, as of May 2026, just passed a separate bill allowing terminally ill patients to use medical cannabis in qualifying healthcare facilities starting August 1. Indiana remains a holdout.

Legal observers note the petition is unlikely to succeed on the merits without additional plaintiffs joining the case. Procedural challenges to DEA rescheduling actions historically face a high bar at the D.C. Circuit, which tends to defer to agency discretion when the administrative record reasonably supports the decision.

The Stakes for Schedule III Cannabis Businesses

For cannabis operators, the lawsuit lands at an awkward moment. Many companies are racing to take advantage of Schedule III's most immediate financial benefit: relief from Section 280E of the Internal Revenue Code, which has barred plant-touching businesses from deducting ordinary expenses for federal tax purposes. Under Schedule III, those deductions become available, freeing up cash flow that operators have already begun modeling into 2026 and 2027 plans.

California's Department of Cannabis Control has issued emergency regulations giving roughly 1,600 state licensees a path to secure a secondary medical license so they can pursue DEA registration before a June deadline. Operators in New York, Illinois, and Massachusetts have begun similar regulatory preparation.

If Rokita's petition is successful — or even if it slows implementation by a year — the financial assumptions baked into operator forecasts will need to be revised downward. Cannabis stocks, which rallied through April and May 2026 on rescheduling optimism, are particularly exposed.

What Happens Next in the D.C. Circuit

The D.C. Circuit typically takes 9 to 18 months to resolve agency-action petitions of this complexity, though the court can expedite cases when the public interest is high. The Justice Department has not yet filed its response.

Industry trade groups including the National Cannabis Industry Association and the U.S. Cannabis Council have signaled they will file amicus briefs supporting the rescheduling. Medical and patient-advocacy groups, including the Multidisciplinary Association for Psychedelic Studies and several state-licensed dispensary associations, are expected to join.

For now, Schedule III remains in effect. DEA registration windows are open, state-level secondary licensing is moving forward, and operators continue to plan for 280E relief. But the Rokita lawsuit serves as a reminder that the political and legal architecture supporting federal cannabis reform is still contested — and that a single appellate ruling could pull the rug out from under thousands of businesses that have already restructured around the change.

What This Means for Consumers and Patients

For most cannabis consumers and patients, the lawsuit will have no immediate effect. State-level legal markets continue to operate under their existing frameworks. Medical patients in active programs will not lose access. Adult-use markets in 24 states remain open.

What could change, depending on how the court rules, is the pace at which pharmaceutical-grade cannabis products move from clinical trials to pharmacy shelves. VERTANICAL's VER-01 — the first cannabis extract granted FDA Breakthrough Therapy Designation for chronic pain — is expected to begin its U.S. pivotal trial under a Schedule III framework. A vacatur could complicate that timeline.

Key Takeaways

• Indiana AG Todd Rokita, joined by Nebraska and Louisiana, filed a May 22, 2026 petition in the D.C. Circuit challenging the federal cannabis rescheduling.
• The lawsuit attacks the rulemaking process and international-treaty compliance, not the underlying medical evidence.
• Schedule III remains in effect during the litigation, and 280E tax relief is still available to compliant operators.
• A ruling in favor of the petitioners could vacate the reclassification and disrupt operator forecasts that assume Schedule III becomes permanent.

Explore cannabis news, find dispensaries, and join the community at Budpedia.